华恒生物：向香港联交所递交H股发行并上市申请

Core Viewpoint - The company has submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange on September 30, 2025, targeting qualified overseas investors and domestic qualified investors under Chinese laws [1] Group 1 - The application for H-share issuance and listing has been officially submitted to the Hong Kong Stock Exchange [1] - The application materials were published on the Hong Kong Stock Exchange website on the same day [1] - The issuance will be limited to qualified overseas investors and domestic qualified investors who are authorized to conduct overseas securities investments according to Chinese laws [1]